Skip to main content

Biomarkers of Malignant Pleural Mesothelioma

  • Chapter
  • First Online:
Biomarkers in Cancer Therapy
  • 625 Accesses

Abstract

Malignant pleural mesothelioma (MPM) is a rare tumor with a poor prognosis. Blood biomarkers of MPM would be useful in clinical practice, as they could aid radiological evaluation by reflecting prognostic information and predicting the effects of treatment. The many reports on MPM blood biomarkers have focused on their utility as screening or diagnostic tests. Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) have been used to aid in the diagnosis of MPM but are not useful as blood biomarkers. The most frequently studied blood biomarker of MPM is the soluble mesothelin-related peptides (SMRPs). Other potential biomarkers are megakaryocyte potentiating factor (MPF), also called N-ERV/mesothelin, which is formed from the same precursor protein as soluble mesothelin; osteopontin, a glycoprotein that mediates cell–matrix interactions; and fibulin-3, an extracellular glycoprotein. A combination of the best-performing marker and highest-value marker, as determined by ongoing research, will likely improve the accuracy and rapidity of MPM diagnosis in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612–6. https://doi.org/10.1016/S0140-6736(03)14794-0.

    Article  CAS  PubMed  Google Scholar 

  2. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937–42. https://doi.org/10.1158/1078-0432.CCR-03-0801.

    Article  CAS  PubMed  Google Scholar 

  3. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317–24. https://doi.org/10.1097/JTO.0b013e318187491c.

    Article  PubMed  Google Scholar 

  4. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82(3):491–8. https://doi.org/10.1016/j.lungcan.2013.09.016.

    Article  PubMed  Google Scholar 

  5. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69(10):895–902. https://doi.org/10.1136/thoraxjnl-2014-205205.

    Article  PubMed  Google Scholar 

  6. Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med. 2010;104(1):149–56. https://doi.org/10.1016/j.rmed.2009.05.017.

    Article  PubMed  Google Scholar 

  7. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541–9. https://doi.org/10.1200/JCO.2011.39.6671.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer. 2017;116(6):731–41. https://doi.org/10.1038/bjc.2017.22.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, et al. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res. 2008;28(6B):3933–6.

    CAS  PubMed  Google Scholar 

  10. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011;6(11):1930–7. https://doi.org/10.1097/JTO.0b013e3182272294.

    Article  PubMed  Google Scholar 

  11. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014;120(21):3311–9. https://doi.org/10.1002/cncr.28875.

    Article  CAS  PubMed  Google Scholar 

  12. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10):2928–35. https://doi.org/10.1158/1078-0432.CCR-06-2144.

    Article  CAS  PubMed  Google Scholar 

  13. Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, et al. Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2016;11(6):900–9. https://doi.org/10.1016/j.jtho.2016.02.006.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int. 2014;2014:419853. https://doi.org/10.1155/2014/419853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417–27. https://doi.org/10.1056/NEJMoa1115050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The south west area mesothelioma and pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112(7):1175–82. https://doi.org/10.1038/bjc.2015.62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5(4):479–83. https://doi.org/10.1097/JTO.0b013e3181d2f008.

    Article  PubMed  Google Scholar 

  18. Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, et al. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 2012;75(2):248–54. https://doi.org/10.1016/j.lungcan.2011.06.007.

    Article  PubMed  Google Scholar 

  19. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989;243(4894 Pt 1):1056–9.

    Article  CAS  PubMed  Google Scholar 

  20. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A. 2014;111(8):3068–73. https://doi.org/10.1073/pnas.1316925111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290–301. https://doi.org/10.1158/0008-5472.CAN-11-3481.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Wu T, Zhang W, Yang G, Li H, Chen Q, Song R, et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016;7(31):50417–27. https://doi.org/10.18632/oncotarget.10413.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol. 2014;171(12):2925–39. https://doi.org/10.1111/bph.12601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res. 1993;53(6):1281–5.

    CAS  PubMed  Google Scholar 

  25. Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, et al. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer. 2017;17(1):212. https://doi.org/10.1186/s12885-017-3209-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kazutoshi Isobe .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Isobe, K. (2019). Biomarkers of Malignant Pleural Mesothelioma. In: Shimada, H. (eds) Biomarkers in Cancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-13-7295-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7295-7_14

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7294-0

  • Online ISBN: 978-981-13-7295-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics